It’s time for an end-of-year review of biotech investing: expert investors share the trends they saw for 2024 and the deals that made a difference. Was 2024 a good year for early-stage investing? Where did larger funds’ money go? What was the geographical diversity of early-stage deals? What’s under and on the radar? What can we expect in 2025? Which therapeutic areas will attract or increase VC interest?
Moderator: Philippe Monteyne, Partner, Aliath Bioventures 
With more than 1,000 international actors from 35+ countries, such as big pharma, emerging and small biotech, diagnostic companies, pre-seed / seed / Series A investors, as well as professionals from tech transfer, academia and research institutions, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment rounds in Life Sciences.
Learn more
Organised by:
WITH THE SUPPORT OF:
INSTITUTIONAL PARTNERS:
"*" indicates required fields
Palais de la Musique et des Congrès
Place de Bordeaux
67000, Strasbourg, FRANCE
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
WARNING: Some fraudulent companies are supposedly providing the attendees list of BioFIT. And some are passing themselves off as being BioFIT organisation members and asking you to pay. Please note that the BioFIT team will never sell you the BioFIT attendees list and never ask for your bank account details to make you pay for hotel bookings, exhibition fees or others, and certainly not over the phone.Please be extremely vigilant.
